2017 | Volume Volume - 2 - Issue Issue - 1

In this issue

Research Article

Open Access Research Article PTZAID:GJCT-2-109

Lenvatinib Suppresses Angiogenesis through the Inhibition of both the VEGFR and FGFR Signaling Pathways

Published On: July 02, 2016 | Pages: 019 - 025

Author(s): Kenji Ichikawa, Saori Watanabe Miyano, Yusuke Adachi, Masahiro Matsuki, Kiyoshi Okamoto and Junji Matsui*

Lenvatinib mesilate (lenvatinib) is an oral multiple-receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of Vascular Endothelial Growth Factor Receptor (VEGFR) 1---3, Fibroblast Growth Factor Receptor (FGFR) 1---4, Platelet-Derived Growth Factor Receptor (PDGFR) , KIT, and RET. The VEGFR and FGFR signaling pathways are the master regula ...

Abstract View Full Article View DOI: 10.17352/gjct.000009

Open Access Research Article PTZAID:GJCT-2-108

A Novel Small-Molecule Integrin Antagonist Inhibits Cells Adhesion Followed By Anoikis in Endothelial Cells - A Comparative Analysis with Cilengitide

Published On: March 18, 2016 | Pages: 009 - 018

Author(s): Agnieszka Christenheit*, Petra Heffeter and Edgar Selzer

Background: Despite the crucial role of integrin receptors in cancer pathogenesis and massive efforts towards establishing clinically relevant drugs, to the present no effective integrin antagonist for the treatment of malignant diseases has been introduced into the clinic. Context and purpose of the study: The purpose of the study was to examine the cellular effec ...

Abstract View Full Article View DOI: 10.17352/gjct.000008

Case Report

Open Access Case Report PTZAID:GJCT-2-110

Gamma-Delta T Cell Acute Lymphoblastic Leukemia: A Single-Center Experience

Published On: December 29, 2016 | Pages: 026 - 029

Author(s): Donnellan W, Mineishi S, Wicker J and Paluri R *

Gamma-delta () T cell neoplasms are a rare disease entity characterized by an aggressive clinical course [1,2]. The management of these neoplasms associated with high incidence of induction failures and poor clinical outcomes [3]. ...

Abstract View | Full Article View | DOI: 10.17352/gjct.000010

Open Access Case Report PTZAID:GJCT-2-106

Primary Leiomyosarcoma of the Mandibular Gingiva

Published On: March 03, 2016 | Pages: 001 - 004

Author(s): Stylianos N Zanakis*, Vasileios Lyris, Sotirios Kyriakou, George Agrogiannis and Penelope Korkolopoulou

Primary oral leiomyosarcomas are exceptionally rare lesions often associated with poor prognosis. We report a case of leiomyosarcoma arising in the anterior mandibular gingiva, which is a non-prevalent site of occurrence. Clinically, the tumor was far from being firm and solid as it is usually described in the literature. Light microscopy failed to confirm the true na ...

Abstract View | Full Article View | DOI: 10.17352/gjct.000006

Short Communication

Open Access Short Communication PTZAID:GJCT-2-111

The Paradoxes of Neoantigenes in Predicting Better Prognosis of Cancer Patients

Published On: December 30, 2016 | Pages: 030 - 031

Author(s): Rui-An Wang*, Qing-Guo Yan and Jian-Guo Shi

Increased neoantigens of cancer generated by mutations are reported to be associated with favorable prognosis of cancer patients. The interesting findings contradict the notions that cancers were caused by accumulation of gene mutations. ...

Abstract View | Full Article View | DOI: 10.17352/gjct.000011

Open Access Mini Review PTZAID:GJCT-2-107

Bortezomib in Anti-Cancer Activity: A Potential Drug

Published On: March 08, 2016 | Pages: 005 - 008

Author(s): Rajagopal Appavu* and Deepa Mohan

26S proteasome is an intracellular; ATP dependent enzymatic complex degrades ubiquitin-tagged proteins and maintains cellular homeostasis. The orderly degraded proteins including cyclins, caspases, Bcl-xL, p53, cell adhesion molecules are involved in cell-cycle progression, tumor suppression, DNA replication, inflammation, and apoptosis. So, proteasome inhibition is a ...

Abstract View Full Article View DOI: 10.17352/gjct.000007